Bluejay Diagnostics, Inc. income statement

In fiscal 2022, Bluejay Diagnostics, Inc. reported revenue of $249,040, operating income of −$9.3m (a -3741.5% margin) and net income of −$9.3m, or −$9.22 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Bluejay Diagnostics, Inc.: income statement, annual
Fiscal year	2022Dec 2022
Revenue	249
Cost of revenue	200
Gross profit	49
Research and development	4,152
Selling, general and administrative	451
Operating income	−9,318
Net income	−9,297
Diluted EPS	−$9.22
Diluted shares (average)	1m
EBITDA	−9,161

US$ thousands unless shown otherwise. Fiscal quarters.

Bluejay Diagnostics, Inc.: income statement, quarterly
Quarter	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022
Revenue	249	0	0
Cost of revenue	200	0	0
Gross profit	49	0	0
Research and development	756	1,380	1,321
Selling, general and administrative	—	146	170
Selling and marketing	81	—	—
General and administrative	1,197	—	—
Operating income	−1,986	−2,810	−2,454
Net income	−1,937	−2,960	−2,386
Diluted EPS	−$800.00	−$1176.00	−$2.36
EBITDA	−1,942	−2,768	−2,423

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Bluejay Diagnostics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bluejay Diagnostics, Inc.